Results 11 to 20 of about 1,044,115 (187)
Synthetic lethality between TP53 and ENDOD1 [PDF]
Nature Communications, 2022 The authors uncover synthetic lethality between TP53 and ENDOD1, which contains an atypical endonuclease domain. Co-depleted G1 cells accumulate single stranded DNA and die.
Zizhi Tang +11 more
doaj +5 more sources
Synthetic Lethality Targeting Polθ [PDF]
Genes, 2022 Research studies regarding synthetic lethality (SL) in human cells are primarily motivated by the potential of this phenomenon to be an effective, but at the same time, safe to the patient’s anti-cancer chemotherapy.
Gabriela Barszczewska-Pietraszek +9 more
core +3 more sources
Modeling synthetic lethality. [PDF]
Genome Biology, 2008 International audienceBACKGROUND: Synthetic lethality defines a genetic interaction where the combination of mutations in two or more genes leads to cell death.
Nolwenn Le Meur +3 more
core +4 more sources
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations [PDF]
Drugs in Context, 2018 Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer.
Marisa C Liu, Krishnansu S Tewari
doaj +2 more sources
Synthetic Lethality Approaches in Acute Lymphoblastic Leukemia
Hemato, 2023 Acute lymphoblastic leukemia (ALL), a remarkable cancer that mainly affects children, has seen commendable advances in its treatment. However, the occurrence of relapses after initial treatments poses a major threat and is one of the leading causes of ...
Francisco Alejandro Lagunas-Rangel +1 more
doaj +2 more sources
Protocol for Comprehensive Synthetic Lethality Screens
STAR Protocols, 2020 Summary: Here, we provide a detailed protocol for synthetic lethality screens in a Jurkat T cell leukemia line using cell death as the readout measuring the combinatorial effect of a pan-PI3K inhibitor (GDC0941) with specific gene depletion by shRNA.
Damia Romero-Moya, Jeroen P. Roose
doaj +5 more sources
Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs [PDF]
Frontiers in OncologyWith the tremendous success of the PARP inhibitor olaparib in clinical practice, synthetic lethality has become an important field for the discovery and development of anticancer drugs.
Xiaoliang Gong +4 more
doaj +2 more sources
Protease addiction and synthetic lethality in cancer [PDF]
Frontiers in Oncology, 2011 The oncogene addiction concept refers to the dependence of cancer cells on the function of the oncogenes responsible for their transformed phenotype, while the term non-oncogene addiction has been introduced to define the exacerbated necessity of the ...
Jose M.P. Freije +2 more
doaj +3 more sources
PARP inhibitors: Synthetic lethality in the clinic [PDF]
Science, 2017 PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors arising in patients who
Ashworth, A +5 more
core +6 more sources
Advances in synthetic lethality modalities for glioblastoma multiforme
Open MedicineGlioblastoma multiforme (GBM) is characterized by a high mortality rate, high resistance to cytotoxic chemotherapy, and radiotherapy due to its highly aggressive nature.
Richard Seidu A.
doaj +2 more sources